Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

GT Biopharma Inc (GTBP)

GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,188
  • Shares Outstanding, K 1,417
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,600 K
  • 60-Month Beta 0.61
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.88
Trade GTBP with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.95 +11.79%
on 09/09/24
2.34 -7.00%
on 08/22/24
-0.07 (-3.11%)
since 08/16/24
3-Month
1.95 +11.79%
on 09/09/24
3.74 -41.71%
on 06/27/24
-0.81 (-27.09%)
since 06/18/24
52-Week
1.95 +11.79%
on 09/09/24
10.66 -79.55%
on 05/20/24
-5.17 (-70.35%)
since 09/18/23

Most Recent Stories

More News
GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

Presented preclinical data demonstration second-generation CD19 targeting Tri-specific Killer Engager (TRIKE®) driving robust NK cell function against B...

GTBP : 2.18 (-3.11%)
GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

Ongoing experiments will evaluate the functionality and efficacy of GTB-7550 in vivoFuture studies will also involve assessments of GTB-7550 TriKE efficacy...

GTBP : 2.18 (-3.11%)
GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update

Presented pre-clinical data at American Association for Cancer Research (AACR 2022), demonstrating GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer...

GTBP : 2.18 (-3.11%)
GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022

- Ongoing experiments will evaluate the functionality and efficacy of the B7H3 TriKE in vivo- Future studies will also involve assessments of the B7H3...

GTBP : 2.18 (-3.11%)
GT Biopharma Announces Closing of $23.7 Million Public Offering

GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on the development and commercialization of its disruptive, target-directed Natural Killer (NK) cell engager immunotherapy...

GTBP : 2.18 (-3.11%)
GT Biopharma Announces Pricing of $23,650,000 Public Offering and Uplisting to The Nasdaq Capital Market

GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology platform today announced the...

GTBP : 2.18 (-3.11%)
Rithem Life Sciences Announces Formation of Board of Directors

Rithem Life Sciences, a Wilmington, Delaware-based medical device company and developer of safe and efficacious life-saving portable products, has announced the formation of its Board of Directors.

GTBP : 2.18 (-3.11%)
MUSA : 515.34 (-2.26%)
BBI : 2.35 (+2.17%)
SEI : 12.64 (-0.63%)
GT Biopharma Announces GTB-3550 TriKE(TM) Reduces Bone Marrow Blast Levels, Improves NK Cell Function and Proliferation, and No Toxicities Observed in AML and MDS Patients

GTB-3550 Interim Results Presented at 62nd American Society of Hematology Annual Meeting and Exposition BEVERLY HILLS, CA / ACCESSWIRE / December 8, 2020 / GT Biopharma, Inc. (OTCQB:GTBP)(GTBP.PA) an immuno-oncology...

GTBP : 2.18 (-3.11%)
GT Biopharma Announces Dr. Greg Berk, M.D. Joins Board of Directors

BEVERLY HILLS, CA / ACCESSWIRE / November 19, 2020 / GT Biopharma, Inc. (OTCQB:GTBP)(GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager...

GTBP : 2.18 (-3.11%)
GT Biopharma Appoints Michael Handelman, CPA as Chief Financial Officer

BEVERLY HILLS, CA / ACCESSWIRE / November 18, 2020 / GT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager...

GTBP : 2.18 (-3.11%)

Business Summary

GT Biopharma Inc. is an immuno-oncology company. It discovers, develops and commercializes drugs of therapeutic molecules for the treatment of cancer, myeloma, osteolytic lesions and other unmet medical needs. GT Biopharma Inc., formerly known as OXIS International Inc., is based in Tampa, Florida.

See More

Key Turning Points

3rd Resistance Point 2.43
2nd Resistance Point 2.36
1st Resistance Point 2.27
Last Price 2.18
1st Support Level 2.11
2nd Support Level 2.04
3rd Support Level 1.95

See More

52-Week High 10.66
Fibonacci 61.8% 7.33
Fibonacci 50% 6.30
Fibonacci 38.2% 5.28
Last Price 2.18
52-Week Low 1.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar